In November 2018, the Trump Administration proposed a rule that would weaken patient protections within Medicare’s Part D prescription drug benefit. Currently, Medicare Part D drug plans are required to comply with the “protected drug classes” policy, which ensure that beneficiaries have access to “all or substantially all” drugs in six specific classes of medicines (like antiretrovirals, antidepressants, antipsychotics, and anticonvulsant agents).
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Assemblyman James Ramos (D-Highland). We look forward to working with Assemblyman Ramos and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On Wednesday, Feb. 20, California Attorney General Xavier Becerra and Chair of Assembly Health, Assemblymember Jim Wood, held a press conference to announce the introduction of legislation, Assembly Bill (AB) 824 (Wood), aimed at enabling the California Department of Justice (DOJ) to go after so-called “pay-for-delay” agreements.
On Feb. 7, the CLSA’s federal government relations team hosted 10 members of CLSA’s board of directors and President & CEO, Mike Guerra, for a full day on Capitol Hill meeting with 9 members of the California delegation.